Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jun 02, 2026
Why Is Celcuity (CELC) Stock Down -22% Today?

Why Is Celcuity (CELC) Stock Down -22% Today?

Key Takeaways

  • CELC shares are falling sharply in premarket trading on June 2, 2026, declining approximately 22% from the prior session's close of $126.18, implying a premarket price near $98.42
  • The primary catalyst is the full detailed data presentation from the PIK3CA mutant cohort of Celcuity's Phase 3 VIKTORIA-1 clinical trial, delivered at the ASCO Annual Meeting in Chicago on June 2 — a long-anticipated event that appears to have triggered a "sell the news" reaction
  • The stock had already rallied dramatically in the months leading up to today on positive topline data, leaving shares particularly vulnerable to a sentiment reversal once concrete details were disclosed
  • Broader biotech sector volatility around major clinical data readouts adds to the pressure, as investors reassess risk/reward after an extended run-up
  • The FDA's PDUFA decision for gedatolisib in the PIK3CA wild-type indication, expected by July 17, 2026, remains the next significant regulatory milestone traders are monitoring

Opening Summary

Celcuity Inc. (CELC) is a Minneapolis-based clinical-stage biotechnology company focused on developing targeted cancer therapies, most notably gedatolisib, a pan-PI3K and mTORC1/2 inhibitor being evaluated for hormone receptor-positive, HER2-negative advanced breast cancer. Shares are down approximately 22% in Tuesday premarket trading, falling from a prior close of $126.18 to an implied level near $98.42. The steep decline follows the presentation of detailed Phase 3 VIKTORIA-1 data at the ASCO Annual Meeting, an event the market had long anticipated and which now appears to have catalyzed significant profit-taking and recalibration of investor expectations.

ASCO Data Presentation and "Sell the News" Dynamics

Celcuity had announced topline results from the PIK3CA mutant cohort of VIKTORIA-1 on April 30, 2026, confirming that the gedatolisib triplet and doublet regimens achieved statistically significant and clinically meaningful improvements in progression-free survival versus alpelisib plus fulvestrant. That announcement sent shares sharply higher, as did prior trial readouts, contributing to a stock that had rallied over 1,000% over the preceding twelve months. The full granular data — including precise hazard ratios, median PFS numbers by arm, subgroup analyses, and a complete safety breakdown — were reserved for the June 2 late-breaking abstract oral session at ASCO. When detailed data is dissected in real time by oncologists, investors, and analysts, even technically positive results can disappoint when specific metrics fail to clear the bar that a dramatically re-rated stock has priced in.

Clinical Data Context

The VIKTORIA-1 trial's PIK3CA mutant cohort evaluated gedatolisib in combination with fulvestrant, with or without palbociclib, in patients with HR+/HER2- locally advanced or metastatic breast cancer who had progressed on prior CDK4/6 inhibitor and aromatase inhibitor therapy. Both the triplet and doublet regimens demonstrated statistically significant PFS improvement over alpelisib and fulvestrant, and both were generally well tolerated with no new safety signals. However, comparisons within the biotech investment community scrutinize not just statistical significance but effect size, comparator arm selection, and how data stacks up relative to competing agents — factors that become fully visible only at an ASCO presentation, and can recalibrate even a clinically meaningful outcome into a relative disappointment against the market's elevated pricing.

Market Context and Trading Activity

CELC's prior close of $126.18 already reflected substantial speculative premium built up over months of anticipatory trading ahead of ASCO. Volume on June 1 was notably subdued at 753,136 shares versus an average of approximately 870,000, suggesting many investors had already positioned ahead of the event and were poised to react swiftly to the data. Biotech stocks tied to late-stage oncology readouts historically experience exaggerated post-ASCO moves — both up and down — because the event represents the culmination of a long-building news cycle, leaving the stock with limited near-term catalysts to sustain valuation once the data is public. Broader biotech sector ETFs and peers with similar PAM-pathway or breast cancer exposure may face sympathetic pressure as the market reassesses the competitive landscape.

Trending AI Robots

For traders navigating high-volatility events like clinical data readouts, Tickeron's Trending AI Robots page offers a curated view of the platform's best-performing AI trading bots under current market conditions. Tickeron operates hundreds of AI-driven bots covering thousands of tickers across multiple strategies, timeframes, and asset classes, but only the top performers — ranked by recent metrics — appear in this Trending section. Bots vary widely in their approach, from momentum and swing strategies to mean-reversion and sector rotation, with each designed for a specific market environment. Traders looking to complement their own research with algorithmic tools may find this resource a useful starting point.

What Comes Next for CELC

The most immediate catalyst on the horizon is the FDA's PDUFA decision date for gedatolisib in the PIK3CA wild-type HR+/HER2- advanced breast cancer indication, expected by July 17, 2026 — a distinct regulatory milestone from today's mutant-cohort data. Approval would mark gedatolisib's first commercial launch and could materially alter the company's trajectory, while a Complete Response Letter would likely extend the sell-off. For the PIK3CA mutant indication, Celcuity has stated it intends to submit a supplemental New Drug Application (sNDA) to the FDA using today's VIKTORIA-1 data, with submissions to other regulatory authorities to follow. The next earnings report is scheduled for August 13, 2026, where management is expected to address pipeline progress and cash runway. CELC remains a pre-revenue, clinical-stage company reporting consistent net losses — $52.8 million in Q1 2026 alone — making it highly sensitive to trial outcomes and regulatory decisions. Analyst price targets and ratings revisions following the ASCO presentation will be closely watched in the sessions ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitation

Related Ticker: CELC

CELC in downward trend: 10-day moving average broke below 50-day moving average on June 04, 2026

The 10-day moving average for CELC crossed bearishly below the 50-day moving average on June 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CELC as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CELC turned negative on May 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

CELC moved below its 50-day moving average on June 01, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CELC entered a downward trend on June 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CELC advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .

CELC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CELC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (79.365) is normal, around the industry mean (19.523). P/E Ratio (0.000) is within average values for comparable stocks, (35.904). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.680). CELC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (0.000) is also within normal values, averaging (353.959).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.84B. The market cap for tickers in the group ranges from 58 to 112.43B. VRTX holds the highest valuation in this group at 112.43B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -7%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was -5%. TVGN experienced the highest price growth at 45%, while ADCT experienced the biggest fall at -71%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -42%. For the same stocks of the Industry, the average monthly volume growth was -16% and the average quarterly volume growth was 3%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 81
Price Growth Rating: 60
SMR Rating: 94
Profit Risk Rating: 93
Seasonality Score: 13 (-100 ... +100)
View a ticker or compare two or three
CELC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a biotechnology company develops novel diagnostic tests

Industry Biotechnology

Profile
Details
Industry
Miscellaneous Commercial Services
Address
16305 36th Avenue North
Phone
+1 763 392-0767
Employees
155
Web
https://www.celcuity.com
Interact to see
Advertisement
Oracle Corporation (ORCL) has shown resilience in a volatile tech sector, maintaining a market capitalization around $590 billion amid broader market fluctuations. The stock trades within its 52-week range, reflecting investor responses to cloud computing demand and competitive pressures. Recent trading sessions have seen downward momentum, influenced by sector-wide reevaluations of AI investments and macroeconomic uncertainties. Despite this, ORCL's forward price-to-earnings ratio and dividend yield position it as a stable player in enterprise software, with focus on its multicloud strategy and partnerships driving long-term value in the latest market cycle.
NuScale Power (SMR) has experienced notable volatility in recent trading sessions, reflecting broader trends in the nuclear energy sector. The stock has traded within a wide range over the latest market cycle, influenced by shifts in investor sentiment toward small modular reactors amid rising energy needs from data centers and AI applications. While the company maintains a market capitalization in the mid-single-digit billions, its price action has been marked by pullbacks from earlier peaks, with momentum indicators suggesting potential stabilization. Broader industry factors, including regulatory support and partnerships, continue to underpin interest, though operational challenges persist. This positions SMR as a high-beta play in the clean energy space, appealing to growth-oriented investors monitoring sector developments.
Monolithic Power Systems (MPWR) has demonstrated robust performance in recent trading sessions, buoyed by its position in the semiconductor industry amid rising demand for power management solutions in AI and data centers. The stock has maintained upward momentum over the latest market cycle, reflecting broader sector trends where technology firms benefit from enterprise investments. With a market capitalization in the mid-$40 billion range and a forward price-to-earnings ratio indicating growth expectations, MPWR continues to attract investor interest. Recent weeks have seen the shares navigate volatility tied to macroeconomic factors, yet overall sentiment remains positive as the company leverages its fabless model to capitalize on efficiency-driven innovations in computing and automotive applications.
Quanta Services (PWR), a leader in infrastructure solutions for electric power, renewables, and communications, has demonstrated resilient performance in recent trading sessions. The stock has maintained upward momentum amid broader market cycles favoring energy and infrastructure sectors, driven by increasing demand for grid modernization and sustainable projects. Trading near its 52-week highs, PWR reflects positive investor sentiment, with a market capitalization exceeding $68 billion and a trailing P/E ratio around 68. Volatility has been moderate, influenced by sector-wide catalysts, positioning the company as a growth-oriented pick in the industrial space. This stock analysis highlights PWR's ability to capitalize on long-term trends in energy transition.
Teradyne (TER), a leader in automated test equipment and industrial robotics, has demonstrated resilient performance amid a favorable semiconductor market cycle. In recent weeks, the stock has maintained upward traction, outperforming broader indices like the Nasdaq, supported by AI-driven demand for chip testing solutions.
Curtiss-Wright Corporation (CW) has demonstrated resilience in recent trading sessions, navigating a period of moderate volatility within the aerospace and defense sector. The stock has shown upward momentum over the latest market cycle, supported by strong demand in commercial and military applications.
CrowdStrike Holdings (CRWD) has shown resilience in the cybersecurity sector amid broader market cycles, with shares experiencing moderate pullbacks in recent weeks following strong year-to-date gains. The stock trades near its upper range, reflecting investor optimism in AI-driven security innovations and platform adoption.
Arista Networks (ANET) has demonstrated resilience in recent trading sessions amid fluctuating tech market conditions. The stock has navigated broader sector headwinds, including competition in cloud networking and varying demand from hyperscale clients.
Galaxy Digital Holdings Ltd. (GLXY), a leading player in digital assets and blockchain investment, has shown resilience in recent trading sessions amid cryptocurrency market dynamics. The stock has navigated volatility driven by Bitcoin's price fluctuations, reflecting broader sector sentiment.
In the ever-shifting healthcare sector, CVS Health (CVS) and UnitedHealth Group (UNH) represent two powerhouse approaches: CVS as a retail pharmacy giant with integrated insurance and services, and UNH as a leading health insurer with diversified operations.
In the competitive retail landscape, American Eagle Outfitters (NYSE: AEO) is showing signs of robust upward potential as it navigates a strong 2025 performance.
In the dynamic world of satellite communications and broadband services, EchoStar Corporation (NASDAQ: SATS) has captured investor attention with a notable technical breakthrough. On December 8, 2025, the stock's 10-day moving average crossed above its 50-day moving average, signaling the onset of a bullish upward trend.
In an era where global investors demand instant access to markets, major players in the financial world are racing to extend trading hours beyond the traditional 9:30 a.m. to 4 p.m. ET window. This push is driven by surging foreign holdings of U.S. equities, which hit $17 trillion last year, and the growing appetite for nonstop trading in a 24/7 digital economy.
In the resilient gold mining sector, IAMGOLD Corporation (NYSE: IAG) has demonstrated an extraordinary uptrend throughout 2025, capitalizing on rising gold prices and operational milestones.
Within the rapidly evolving automotive retail landscape, Carvana Co. (NYSE: CVNA) has emerged as one of 2025’s standout performers. Once viewed as a highly volatile name, the company has transformed into a market leader as demand for online vehicle purchasing accelerates
Microsoft (MSFT) emerges as the AI-favored stock in 2025, outperforming Apple (AAPL) with a 16% year-to-date gain, compared to Apple’s 10% rise. The advantage stems from Microsoft’s deeper enterprise AI integration, accelerating cloud growth, and scalable software ecosystem.
ExxonMobil (XOM) emerges as the AI-preferred energy stock in 2025, posting a 10% year-to-date gain compared with Chevron’s (CVX) 2% increase. Stronger upstream production, exposure to high-growth assets, and expanding low-carbon initiatives support XOM’s momentum. Tickeron’s AI models signal continued upside for XOM, while CVX shows signs of overbought conditions and elevated downside risk.
Tesla (TSLA) emerges as the AI-preferred EV stock in 2025, posting a 19% year-to-date gain, while BYD (BYDDY) has declined 82%, reflecting diverging momentum across the global EV market. Tickeron’s AI trading bots indicate strong bullish conditions for TSLA, supported by positive momentum signals, whereas BYDDY shows sustained bearish trends.
Broadcom (AVGO) emerges as the AI-preferred semiconductor stock in 2025, posting a 48% year-to-date gain, compared with 37% for NVIDIA (NVDA), supported by stronger diversification across networking, infrastructure, and custom AI chips.